We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has hit Oeyama-Moto Cancer Research Foundation’s IRB for failing to define its operational protocol, leading to inadequate communication with clinical investigators and meager documentation. Read More
The FDA has thrown a wrench into Chiasma’s plans to market Mycapssa, the company’s acromegaly candidate, issuing a complete response letter that asks for more data. Read More